Chlorpromazine hydrochloride

Dopamine receptor ，Potassium channel

355.33

DMSO : 50 mg/mL
Water : 50 mg/mL
Ethanol : 50 mg/mL

白色粉末

Chlorpromazine affects miniature IPSCs (mIPSCs) by decreasing the binding (kon) and by increasing the unbinding (koff) rates of GABAARs. Chlorpromazine modulates activated TRPA1 currents in a voltage-dependent way, leading to a block at positive potentials and an increased open probability at negative potentials.

Chlorpromazine independently down-regulates the production of various T cell-derived lymphokines (IL-2, IFN-gamma, IL-4, TNF, and GM-CSF) and up-regulates the secretion of IL-10 in an in vivo model of acute superantigen-driven immune activation. Chlorpromazine -mediated amplification of the SEB-driven Chlorpromazine secretion is accompanied by an enhanced IL-10 mRNA accumulation. Chlorpromazine protects mice, normal or adrenalectomized, and guinea pigs against lethality of LPS, and inhibits TNF serum levels. Chlorpromazine protects against LPS lethality when administered 30 minutes (min) before, simultaneously, or up to 10 min after LPS and is ineffective when given 30 min after LPS, paralleling the inhibitory effect on TNF production. Chlorpromazine significantly inhibits LPS lethality and hepatotoxicity in mice sensitized to LPS toxicity by actinomycin D, whereas under these conditions DEX is inactive. Chlorpromazine protects brain tissue from hypoxia-induced irreversible loss of synaptic transmission in rats. Chlorpromazine also significantly delays the occurrence of the hypoxia-induced spreading depression (SD) in rats.

盐酸氯丙嗪；Chlorpromazine HCl

C₁₇H₂₀Cl₂N₂S

69-09-0